Blood and lymphatic system disorders – page 58

Study on Itacitinib for Treating Non-Severe Hemophagocytic Lymphohistiocytosis in Adults

Study on Itacitinib for Treating Non-Severe Hemophagocytic Lymphohistiocytosis in Adults

Access to Mepolizumab for Patients with Hypereosinophilic Syndrome

Access to Mepolizumab for Patients with Hypereosinophilic Syndrome

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Study on the Effects of Mitapivat for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

Study on the Effects of Mitapivat for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

Study on Emicizumab for Patients with Mild or Moderate Hemophilia A Without FVIII Inhibitors

Study on Emicizumab for Patients with Mild or Moderate Hemophilia A Without FVIII Inhibitors

Study on Isatuximab and Dexamethasone for Patients with Relapsed Multiple Myeloma Undergoing Stem Cell Transplantation

Study on Isatuximab and Dexamethasone for Patients with Relapsed Multiple Myeloma Undergoing Stem Cell Transplantation

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Study on Adding Isatuximab to Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Study of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Study of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Study of Mitapivat for Adults with Sickle Cell Disease

Study of Mitapivat for Adults with Sickle Cell Disease

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

Study on the Safety and Effectiveness of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Study on the Safety and Effectiveness of Glofitamab and Obinutuzumab for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Study on the Effectiveness of Ivosidenib in Patients with IDH1 Mutated Myelodysplastic Syndrome